Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Amortization of Deferred Charges (2021 - 2022)

Historic Amortization of Deferred Charges for SAB Biotherapeutics (SABS) over the last 2 years, with Q3 2022 value amounting to $24717.0.

  • SAB Biotherapeutics' Amortization of Deferred Charges fell 4009.31% to $24717.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $138939.0, marking a year-over-year change of. This contributed to the annual value of $164983.0 for FY2021, which is 3.21% down from last year.
  • SAB Biotherapeutics' Amortization of Deferred Charges amounted to $24717.0 in Q3 2022, which was down 4009.31% from $31809.0 recorded in Q2 2022.
  • Over the past 5 years, SAB Biotherapeutics' Amortization of Deferred Charges peaked at $41259.0 during Q1 2021, and registered a low of $24717.0 during Q3 2022.